Bio-Rad Laboratories Inc. - Ordinary Shares - Class A
BIO
Get informed when a big investor buys or sells
+ FollowMarket Cap$9.49B
Close$
$161.55
55.3% downside
Current Fair Value
55.3% downsideOvervalued by 55.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $9.49 Billion |
|---|---|
| Enterprise Value | $10.25 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $27.87 |
| Beta | 1.09 |
| Outstanding Shares | 26,746,000 |
Return
| Return on Equity | 3.10% |
|---|---|
| Return on Assets | 2.17% |
| Return on Invested Capital | -6.18% |
Valuation & Multiples
| P/E Ratio | 42.31 |
|---|---|
| PEG | 250.88 |
| Price to Sales | 3.76 |
| Price to Book Ratio | 1.35 |
| Enterprise Value to Revenue | 3.96 |
| Enterprise Value to EBIT | -17.85 |
| Enterprise Value to Net Income | 46 |
| Total Debt to Enterprise | 0.12 |
| Debt to Equity | 0.18 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 4, 2026
EPS Estimate
$1.75
Average shareholder expectationRevenue Estimate
$623.99 M
Average shareholder expectationNext Earnings Call
Expected Date
October 29, 2026
EPS Estimate
$2.23
Average shareholder expectationRevenue Estimate
$650.65 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 20.14% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 24.52%▼ 49.59% |
|---|---|
| Total Invested | $1.94B▼ 65.15% |
| Investors Holding | 181▼ 216.00% |
ESG Score
No data
About Bio-Rad Laboratories Inc.
CEO: Norman Schwartz